Meeting
2015 Breast Cancer Symposium
Eribulin and carboplatin in heavily pretreated patients with metastatic breast cancer: A single institution experience.
Authors
Patricia Martin Romano
Clinica Universidad De Navarra, Pamplona, Spain
Patricia Martin Romano , Iosune Baraibar , Oscar Fernández-Hidalgo , Marta Santisteban , Jaime Espinós , Diego Salas , Pablo Sala , Itziar Gardeazabal , Leyre Zubiri Oteiza , Jose M. Aramendia
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Systemic Therapy, Survivorship, and Health Policy
Track
Systemic Therapy,Local/Regional Therapy,Survivorship and Health Policy
Sub Track
Advanced Disease
Citation
J Clin Oncol 33, 2015 (suppl 28S; abstr 122)
DOI
10.1200/jco.2015.33.28_suppl.122
Abstract #
122
Poster Bd #
F5
Abstract Disclosures
Similar Posters
Poster
2011 ASCO Annual Meeting
The relationship between age and survival outcomes for eribulin in metastatic breast cancer.
First Author: C. Twelves
Poster
2022 ASCO Annual Meeting
Real-world treatment patterns and outcomes among patients (pts) with second-line (2L) and third-line (3L) metastatic triple-negative breast cancer (mTNBC) in England using the Cancer Analysis System (CAS).
First Author: Lawrence Chang
Poster
2015 ASCO Annual Meeting
Combination of eribulin (E) and capecitabine (C) in elderly metastatic breast cancer (MBC): Update of a new option suitable in older elderly.
First Author: Ignazio Ugo Carreca
Poster
2015 Gastrointestinal Cancers Symposium
Paclitaxel, carboplatin, and capecitabine (TCX) with and without radiation in locally advanced and metastatic distal esophageal and esophagogastric junction cancer: A single-center retrospective review.
First Author: Peter Joel Hosein